These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 16707471

  • 1. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tüting T.
    Cancer Res; 2006 May 15; 66(10):5427-35. PubMed ID: 16707471
    [Abstract] [Full Text] [Related]

  • 2. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.
    Cancer Res; 2009 Aug 01; 69(15):6265-74. PubMed ID: 19622767
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.
    J Gene Med; 1999 Aug 01; 1(6):400-6. PubMed ID: 10753065
    [Abstract] [Full Text] [Related]

  • 4. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
    Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN.
    J Surg Res; 2002 Feb 01; 102(2):137-43. PubMed ID: 11796010
    [Abstract] [Full Text] [Related]

  • 5. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.
    Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, Heukamp LC, Gütgemann I, Buettner R, Malumbres M, Barbacid M, Merlino G, Tüting T.
    Am J Pathol; 2006 Aug 01; 169(2):665-72. PubMed ID: 16877364
    [Abstract] [Full Text] [Related]

  • 6. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH, Liu C, Wan YH.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 01; 28(9):658-61. PubMed ID: 17274369
    [Abstract] [Full Text] [Related]

  • 7. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
    Steitz J, Brück J, Knop J, Tüting T.
    Gene Ther; 2001 Aug 01; 8(16):1255-63. PubMed ID: 11509959
    [Abstract] [Full Text] [Related]

  • 8. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
    Brück J, Steitz J, Strand D, Tüting T.
    J Gene Med; 2005 May 01; 7(5):613-20. PubMed ID: 15580620
    [Abstract] [Full Text] [Related]

  • 9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 01; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 10. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
    Steitz J, Tormo D, Schweichel D, Tüting T.
    Cancer Gene Ther; 2006 Mar 01; 13(3):318-25. PubMed ID: 16151477
    [Abstract] [Full Text] [Related]

  • 11. Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance.
    Landsberg J, Gaffal E, Cron M, Kohlmeyer J, Renn M, Tüting T.
    Pigment Cell Melanoma Res; 2010 Oct 01; 23(5):649-60. PubMed ID: 20649939
    [Abstract] [Full Text] [Related]

  • 12. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP, Bogaars H, Wolf SF, Hearing VJ, Wanebo HJ.
    Int J Oncol; 1998 Aug 01; 13(2):361-74. PubMed ID: 9664134
    [Abstract] [Full Text] [Related]

  • 13. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M, Küpcü Z, Schüller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T.
    Cancer Res; 2002 Oct 01; 62(19):5489-94. PubMed ID: 12359758
    [Abstract] [Full Text] [Related]

  • 14. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH, Wan YH.
    Zhonghua Yi Xue Za Zhi; 2005 Jun 22; 85(23):1596-600. PubMed ID: 16185524
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
    Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG.
    Gene Ther; 1998 Jul 22; 5(7):975-83. PubMed ID: 9813669
    [Abstract] [Full Text] [Related]

  • 16. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
    Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ.
    Cancer Res; 2005 Nov 15; 65(22):10555-61. PubMed ID: 16288048
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
    Rossi GR, Mautino MR, Awwad DZ, Husske K, Lejukole H, Koenigsfeld M, Ramsey WJ, Vahanian N, Link CJ.
    J Immunother; 2008 Nov 15; 31(6):545-54. PubMed ID: 18528300
    [Abstract] [Full Text] [Related]

  • 18. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG.
    Cancer Res; 2005 Mar 01; 65(5):2009-17. PubMed ID: 15753401
    [Abstract] [Full Text] [Related]

  • 19. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.
    Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A.
    Vaccine; 2008 Sep 15; 26(39):5046-57. PubMed ID: 18680779
    [Abstract] [Full Text] [Related]

  • 20. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J, Brück J, Lenz J, Knop J, Tüting T.
    Cancer Res; 2001 Dec 15; 61(24):8643-6. PubMed ID: 11751377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.